AU2022410646A1 - Uses of bicyclic compounds for the treatment of diseases - Google Patents

Uses of bicyclic compounds for the treatment of diseases Download PDF

Info

Publication number
AU2022410646A1
AU2022410646A1 AU2022410646A AU2022410646A AU2022410646A1 AU 2022410646 A1 AU2022410646 A1 AU 2022410646A1 AU 2022410646 A AU2022410646 A AU 2022410646A AU 2022410646 A AU2022410646 A AU 2022410646A AU 2022410646 A1 AU2022410646 A1 AU 2022410646A1
Authority
AU
Australia
Prior art keywords
compound
alkyl
mmol
halo
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022410646A
Other languages
English (en)
Inventor
Douglas Boatman
Kevin Church
Jewel JOHNSTON
Leen Kawas
Robert Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leonabio Inc
Original Assignee
Leonabio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leonabio Inc filed Critical Leonabio Inc
Publication of AU2022410646A1 publication Critical patent/AU2022410646A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2022410646A 2021-12-17 2022-12-16 Uses of bicyclic compounds for the treatment of diseases Pending AU2022410646A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163290783P 2021-12-17 2021-12-17
US63/290,783 2021-12-17
US202263312696P 2022-02-22 2022-02-22
US63/312,696 2022-02-22
PCT/US2022/053113 WO2023114456A1 (en) 2021-12-17 2022-12-16 Uses of bicyclic compounds for the treatment of diseases

Publications (1)

Publication Number Publication Date
AU2022410646A1 true AU2022410646A1 (en) 2024-05-30

Family

ID=86773494

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022410646A Pending AU2022410646A1 (en) 2021-12-17 2022-12-16 Uses of bicyclic compounds for the treatment of diseases

Country Status (11)

Country Link
US (1) US20250041307A1 (https=)
EP (1) EP4448100A4 (https=)
JP (1) JP2024546600A (https=)
KR (1) KR20240121239A (https=)
AU (1) AU2022410646A1 (https=)
CA (1) CA3240896A1 (https=)
CL (1) CL2024001748A1 (https=)
IL (1) IL313039A (https=)
MX (1) MX2024005884A (https=)
TW (1) TW202339756A (https=)
WO (1) WO2023114456A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025515045A (ja) * 2022-05-04 2025-05-13 アティラ・ファーマ・インコーポレイテッド 神経炎症病態を治療する方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
AU2003284120A1 (en) * 2002-10-17 2004-05-04 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
EP2155226A4 (en) * 2007-06-14 2010-07-28 Univ California COMPOUNDS FOR INHIBITING THE PROTEIN AGGREGATION AND METHOD FOR THE PRODUCTION AND USE THEREOF
KR20130139895A (ko) * 2010-09-02 2013-12-23 다케다 야쿠힌 고교 가부시키가이샤 경도인지 장애의 치료 또는 예방용 융합 트리아졸
CA2817975C (en) * 2010-11-16 2020-03-31 Michael Kahn Cbp/catenin antagonists for enhancing asymmetric division of somatic stem cells
AP2014007606A0 (en) * 2011-10-07 2014-05-31 Takeda Pharmaceutical 1-Arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
CN119684295A (zh) * 2020-11-02 2025-03-25 雅斯娜制药公司 用于治疗疾病的双环化合物及其用途

Also Published As

Publication number Publication date
CL2024001748A1 (es) 2024-11-22
WO2023114456A1 (en) 2023-06-22
TW202339756A (zh) 2023-10-16
CA3240896A1 (en) 2023-06-22
KR20240121239A (ko) 2024-08-08
EP4448100A4 (en) 2025-10-22
US20250041307A1 (en) 2025-02-06
IL313039A (en) 2024-07-01
MX2024005884A (es) 2024-05-29
JP2024546600A (ja) 2024-12-26
EP4448100A1 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
AU2021371026A9 (en) Bicyclic compounds and uses thereof for the treatment of diseases
AU2022255486A1 (en) Nek7 inhibitors
AU2022410646A1 (en) Uses of bicyclic compounds for the treatment of diseases
EP4518865A1 (en) Methods of treating neuroinflammatory conditions
EP4518866A1 (en) Methods of treating fibrosis
TWI918751B (zh) 用於治療疾病之雙環化合物及其用途
EA049703B1 (ru) Бициклические соединения и их применение для лечения заболеваний
EA050745B1 (ru) Применение бициклических соединений для лечения заболеваний
AU2023265053A1 (en) Methods of treating neuropathies.
CN118382441A (zh) 双环化合物用于治疗疾病的用途
HK40113746A (zh) 双环化合物用於治疗疾病的用途
HK40122844A (zh) 用於治疗疾病的双环化合物及其用途
HK40097563A (zh) 用於治疗疾病的双环化合物及其用途
WO2025250930A1 (en) Hdac6 inhibitors and method of their use

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: TO AMEND THE APPLICANT NAME TO LEONABIO, INC.